Glioblastoma Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Growing Prevalence of Glioblastoma Multiforme
   3. Market Restraints
      1. Limited Treatment Success and High Recurrence Rates
      2. Complexity of Blood-Brain Barrier (BBB)
   4. Market Opportunities
      1. Robust Drug Pipeline
   5. Market Trends
      1. Rising Emphasis on Immunotherapies
5. MARKET SEGMENTATION
   1. By Treatment
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
   2. By Drug Class
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
   3. By End-use
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centres
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Arbor Pharmaceuticals, LLC
      2. Amneal Pharmaceuticals
      3. Amgen, Inc.
      4. F. Hoffmann-La Roche Ltd.
      5. Karyopharm Therapeutics, Inc.
      6. Merck & Co., Inc.
      7. Pfizer Inc.
      8. Sun Pharmaceutical Industries Ltd.
      9. Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
      10. Teva Pharmaceutical Industries Ltd.

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Glioblastomamarket?

The global market of Glioblastoma is projected to reach USD 6.57 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Glioblastomamarket?

The global Glioblastoma market has an estimated annual growth rate of 9.5% .

Q.3. What are the recent trends of Glioblastomamarket?

Rising Emphasis on Immunotherapiesis one of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Glioblastoma?

The major companies profiled in this report include Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Amgen, Inc., F. Hoffmann-La Roche Ltd., Karyopharm Therapeutics, Inc., Merck & Co., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.), Teva Pharmaceutical Industries Ltd. among others.

Q.5. Which region is estimated to held highest CAGR inGlioblastomamarket?

North America is estimated to hold biggest share in the market for Glioblastoma.